Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

100%

4 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 4(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01253356Phase 4Terminated

ACTIONS - Aortic Counterpulsation to Improve Outcomes in Noncardiac Surgery

Role: lead

NCT00833612Phase 4Completed

Counterpulsation Reduces Infarct Size Pre-PCI for AMI

Role: lead

NCT00824109Phase 4Unknown

Prospective, Multicenter Study of the Second Generation Antimicrobial Graft in the Abdominal Position

Role: lead

NCT00007657Phase 3Completed

Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation

Role: collaborator

All 4 trials loaded